CCR5 antagonism in HIV infection: ways, effects, and side effects.
Corbeau
Pierre
P
Unité Fonctionnelle d'Immunologie, CHU de Nîmes, Nîmes, France.
Reynes
Jacques
J
D065100:CCR5 Receptor Antagonists; D024882:Drug Resistance, Viral; D015699:HIV Envelope Protein gp120 / Q000378:metabolism; D023581:HIV Fusion Inhibitors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance; D019713:Receptors, CCR5 / Q000276:immunology / Q000378:metabolism; D016176:T-Lymphocyte Subsets / Q000276:immunology
D065100:CCR5 Receptor Antagonists; D015699:HIV Envelope Protein gp120; D023581:HIV Fusion Inhibitors; D019713:Receptors, CCR5; C514793:gp120 protein, Human immunodeficiency virus 1